Chikungunya future or investigational therapies
|
Chikungunya Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Chikungunya future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Chikungunya future or investigational therapies |
|
Risk calculators and risk factors for Chikungunya future or investigational therapies |
Future Therapies
| Chloroquine | Ribavirin | 6-Azauridine | Arbidol | Harringtonine | |
|---|---|---|---|---|---|
| Assay type | In vitro (vero cells) | Human | In vitro (vero cells) | In vitro (vero and primary human fibroblast cells) | In vitro (BHK21 cells) |
| Hypothesized target | Disrupted endosome-mediated CHIKV internalization, possibly through the prevention of endosomal acidification. | Can interact with the intracellular viral RNA production. | Inhibition of orotidine monophosphate decarboxylase, an enzyme involved in the de novo biosynthesis of pyrimidine, cytidine, and thymidine. | Inhibition of virus mediated fusion and blocking of the viral entry into the target cells through inhibition of glycoprotein conformational changes that are essential for the fusion process. | Affects CHIKV RNA production inside the infected cell as well as viral protein expression such as the nsP3 and the E2 proteins. |
| Advantages | |||||
| Disadvantages | |||||
| References | |||||
| Table adapted from | |||||